PA8500101A1 - Composiciones y métodos para tratar condiciones alérgicas e inflamatorias con tos - Google Patents

Composiciones y métodos para tratar condiciones alérgicas e inflamatorias con tos

Info

Publication number
PA8500101A1
PA8500101A1 PA20008500101A PA8500101A PA8500101A1 PA 8500101 A1 PA8500101 A1 PA 8500101A1 PA 20008500101 A PA20008500101 A PA 20008500101A PA 8500101 A PA8500101 A PA 8500101A PA 8500101 A1 PA8500101 A1 PA 8500101A1
Authority
PA
Panama
Prior art keywords
inflammatory conditions
methods
compositions
antihistamine
treat
Prior art date
Application number
PA20008500101A
Other languages
English (en)
Inventor
Lugo Sergio Rolando Ulloa
Ramos Jose De Jesus Villacampa
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PA8500101A1 publication Critical patent/PA8500101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN MÉTODOS PARA TRATAR Y/O PREVENIR CONDICIONES ALÉRGICAS E INFLAMATORIAS CON TOS EN HUMANOS QUE REQUIERAN DICHO TRATAMIENTO Y/O PREVENCIÓN, LOS CUALES COMPRENDEN ADMINISTRAR UNA CANTIDAD EFECTIVA DE UNA ANTIHISTAMINA NO SEDANTE EN COMBINACIÓN CON UN EXPECTORANTE; LAS MODALIDADES QUE SE PREFIEREN INCLUYEN AQUELLAS EN LAS QUE LA ANTIHISTAMINA NO SEDANTE ES LORATADINA Y EL EXPECTORANTE ES AMBROXOL; SE PROVEEN TAMBIÉN COMPOSICIONES FARMACÉUTICAS NOVEDOSAS PARA TRATAR Y/O PREVENIR CONDICIONES ALÉRGICAS E INFLAMATORIAS CON TOS EN HUMANOS, LAS CUALES COMPRENDEN UNA CANTIDAD EFECTIVA DE UNA ANTIHISTAMINA NO SEDANTE EN COMBINACIÒN CON UN EXPECTORANTE Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE.
PA20008500101A 2000-03-30 2000-08-17 Composiciones y métodos para tratar condiciones alérgicas e inflamatorias con tos PA8500101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19331000P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
PA8500101A1 true PA8500101A1 (es) 2002-09-17

Family

ID=22713096

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008500101A PA8500101A1 (es) 2000-03-30 2000-08-17 Composiciones y métodos para tratar condiciones alérgicas e inflamatorias con tos

Country Status (13)

Country Link
CN (1) CN1422162A (es)
AR (1) AR025308A1 (es)
AU (2) AU4786701A (es)
BR (1) BR0003648A (es)
CO (1) CO5200779A1 (es)
CR (1) CR6232A (es)
NZ (1) NZ520826A (es)
PA (1) PA8500101A1 (es)
PE (1) PE20010576A1 (es)
SG (1) SG96611A1 (es)
TW (1) TWI243671B (es)
WO (1) WO2001074341A2 (es)
ZA (1) ZA200102605B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323662C (zh) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用
WO2005123052A1 (fr) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Composition medicamenteuse contenant de l'ambroxol et de l'erdosteine ou de l'acetylcysteine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
AU7604094A (en) * 1993-09-07 1995-03-27 Procter & Gamble Company, The Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen

Also Published As

Publication number Publication date
TWI243671B (en) 2005-11-21
AR025308A1 (es) 2002-11-20
BR0003648A (pt) 2002-01-02
SG96611A1 (en) 2003-06-16
CR6232A (es) 2008-12-01
WO2001074341A3 (en) 2002-05-16
AU4786701A (en) 2001-10-15
AU2001247867B2 (en) 2005-09-01
CN1422162A (zh) 2003-06-04
ZA200102605B (en) 2001-10-03
CO5200779A1 (es) 2002-09-27
WO2001074341A2 (en) 2001-10-11
NZ520826A (en) 2004-07-30
PE20010576A1 (es) 2001-05-08

Similar Documents

Publication Publication Date Title
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
NO20034056D0 (no) Proliferative sykdommer
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
CR6210A (es) Composiciones de celecoxib
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
AR109263A2 (es) Composición que comprende moxidectina
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
NO20070580L (no) Behandling av cancer.
BR0313611A (pt) Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
AR021155A1 (es) Tratamiento de desordenes neuroticos
AR028502A1 (es) Tratamiento de condiciones inflamatorias alérgicas
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
PA8500101A1 (es) Composiciones y métodos para tratar condiciones alérgicas e inflamatorias con tos